KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBT: 2009-2025

Historic EBT for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $9.0 million.

  • Jazz Pharmaceuticals' EBT fell 95.50% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.2 million, marking a year-over-year decrease of 41.49%. This contributed to the annual value of $470.4 million for FY2024, which is 57.87% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' EBT stood at $9.0 million, which was up 108.23% from -$109.8 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' EBT's 5-year high stood at $200.8 million during Q3 2024, with a 5-year trough of -$340.0 million in Q4 2022.
  • Its 3-year average for EBT is $66.8 million, with a median of $71.7 million in 2023.
  • Per our database at Business Quant, Jazz Pharmaceuticals' EBT slumped by 658.41% in 2022 and then spiked by 771.16% in 2023.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' EBT stood at -$44.8 million in 2021, then plummeted by 658.41% to -$340.0 million in 2022, then skyrocketed by 118.10% to $61.5 million in 2023, then skyrocketed by 116.52% to $133.2 million in 2024, then plummeted by 95.50% to $9.0 million in 2025.
  • Its EBT was $9.0 million in Q3 2025, compared to -$109.8 million in Q2 2025 and $133.2 million in Q4 2024.